Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.

Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.

Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.